International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

placeholder

TDM in Oncology

Last Updated: Thursday, 29 April 2021 09:14
Gareth Veal

Chair

Gareth Veal
Newcastle upon Tyne, UK

 contactus273x169

Contact Us
Scientific Committees
TDM in Oncology Committee

Background & Purpose of the Committee

  • Creating and promoting awareness of the need for TDM in cancer therapy,
  • Stimulating studies which demonstratethe utility in improving patient outcomes,
  • Education of the IATDMCT members on advances and opportunities in the area,
  • Education of medical oncologists and regulatory authorities of the importance of TDM in oncology,
  • Development of consensus guidelines for implementationncology.

Scope of the Oncology Committee is:

  • TDM for cancer treatment in hematology and oncology,
  • Chemotherapy, molecular targeting therapy, hormonal therapy and immunotherapy,
  • Topics relating to drug concentrations in blood, pharmacogenomics and other biomarkers for the benefit of precision medicine.

Activities Planned/Committee Initiatives Currently in Progress

  • Consensus guideline document for TDM of busulfan
  • Consensus guideline document for TDM of imatinib
  • Consensus guideline document for TDM of paclitaxel
  • Support the 2020 meetings with workshops and symposia

Past Years' Activities Held/Committee Initiatives

  • Consensus guideline document for TDM of 5-Fluorourac.
  • Support the 2019 meetings with workshops and symposia